Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Previous exposure to hepatitis B virus (HBV) may increase the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. We aim to study the impact of previous HBV infection on the severity and outcomes of patients with nonalcoholic fatty liver disease (NAFLD). METHODS: This was a multicenter study of 489 patients with biopsy-proven NAFLD and 69 patients with NAFLD-related or cryptogenic HCC. Antihepatitis B core antibody (anti-HBc) was used to detect the previous HBV infection. RESULTS: In the biopsy cohort, positive anti-HBc was associated with lower steatosis grade but higher fibrosis stage. 18.8% and 7.5% of patients with positive and negative anti-HBc had cirrhosis, respectively (P < 0.001). The association between anti-HBc and cirrhosis remained significant after adjusting for age and metabolic factors (adjusted odds ratio 2.232; 95% confidence interval, 1.202–4.147). At a mean follow-up of 6.2 years, patients with positive anti-HBc had a higher incidence of HCC or cirrhotic complications (6.5% vs 2.2%; P = 0.039). Among patients with NAFLD-related or cryptogenic HCC, 73.9% had positive anti-HBc. None of the patients had positive serum HBV DNA. By contrast, antihepatitis B surface antibody did not correlate with histological severity. DISCUSSION: Positive anti-HBc is associated with cirrhosis and possibly HCC and cirrhotic complications in patients with NAFLD. Because a significant proportion of NAFLD-related HCC may develop in noncirrhotic patients, future studies should define the role of anti-HBc in selecting noncirrhotic patients with NAFLD for HCC surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis
Wah Kheong, C., Nik Mustapha, N. R., & Mahadeva, S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.016 · Cited by 264
Self-citationChoi, H. S. J., Brouwer, W. P., Zanjir, W. M. R., de Man, R. A., Feld, J. J., Hansen, B. E., Janssen, H. L. A., & Patel, K. (2020) · Hepatology · doi:10.1002/hep.30857 · Cited by 211
Wang, Y., Wong, G. L.-H., He, F.-P., Sun, J., Chan, A. W.-H., Yang, J., Shu, S. S.-T., Liang, X., Tse, Y. K., Fan, X.-T., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318841 · Cited by 42
Self-citation
Cited by
Razavi-Shearer, D., Gamkrelidze, I., Pan, C., Jia, J., Berg, T., Gray, R., Lim, Y.-S., Chen, C.-J., Ocama, P., Desalegn, H., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00197-8 · Cited by 441
Self-citationLin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA · doi:10.1001/jama.2024.1447 · Cited by 250
Self-citationNAFLD and HBV interplay - related mechanisms underlying liver disease progression
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M., & Triantos, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965548 · Cited by 70
Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion
Shi, Y.-W., Yang, R.-X., & Fan, J.-G. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i26.3971 · Cited by 47
Metadata
- Authors
- Chan, T. T., Chan, W. K., Wong, G. L.-H., Chan, A. W.-H., Nik Mustapha, N. R., Chan, S. L., Chong, C. C.-N., Mahadeva, S., Shu, S. S.-T., Lai, P. B.-S., Chan, H. L.-Y., & Wong, V. W.-S.
- Venue
- American Journal of Gastroenterology
- Published
- 2020-03-09
- Volume
- 115
- Issue
- 6
- Pages
- 867-875
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W3011277536
- Cited by
- 62
- References
- 7
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.14309/ajg.0000000000000588
- The paper
- Chan, T. T., Chan, W. K., Wong, G. L.-H., Chan, A. W.-H., Nik Mustapha, N. R., Chan, S. L., Chong, C. C.-N., Mahadeva, S., Shu, S. S.-T., Lai, P. B.-S., Chan, H. L.-Y., & Wong, V. W.-S. (2020). Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.